
SFARI is writing to assure you that the health and well-being of your lab members is very much in our minds during the COVID-19 epidemic. We encourage you to do all that is necessary to maintain their health as we face this unprecedented challenge.

SFARI is writing to assure you that the health and well-being of your lab members is very much in our minds during the COVID-19 epidemic. We encourage you to do all that is necessary to maintain their health as we face this unprecedented challenge.

SFARI is pleased to announce that 10 Director Awards were awarded in 2019. These projects include, but are not limited to, studies that aim to enhance existing SFARI-sponsored cohorts and collections, generate novel resources (e.g., animal models) or did not fit into an existing investigator-initiated request for applications.

SFARI has recently implemented a number of changes to SFARI Gene, including modification of the gene scoring, copy number variant, animal models and protein interaction modules. Curation of the human gene module will continue as before.

SFARI announces that it has selected five fellows in response to the 2019 Bridge to Independence Award request for applications.

Funds donated by SFARI to Gordon Research Conferences will now be allocated to support attendance of eligible early-career (pre-tenure) women, early-career trainees from historically underrepresented groups and scientists from the following ethnic and racial groups: Hispanic or Latino, American Indian or Alaska Native, Black or African American, Native Hawaiian or Other Pacific Islander.

SFARI is now curating a set of zebrafish lines to study autism spectrum disorder. This includes mutant lines for 12 ASD risk genes, four of which are currently available to researchers and eight that will be available later this year.

SFARI director Louis Reichardt will leave SFARI this coming October.

SFARI has awarded four grants in response to the 2019 Novel Outcome Measures in Autism Spectrum Disorder (ASD) request for applications. These grants will support the development and validation of outcome measures aimed at assessing core symptoms of ASD and behavioral changes following treatment.